Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, and skyping has, of course, returned. What else to do but fire up the coffee kettle for a cup of stimulation and dig in. On that note, we bring you the latest round of tidbits and hope these help you on your journey. Have a splendid day and do keep in touch. …
Gilead Sciences (GILD) increased the U.S. prices of many of its major products on March 16 by 4.9 percent, including all of its HIV medications, but excluding its hepatitis C treatments and the Yescarta CAR-T therapy, according to Cowen analyst Phil Nadeau. He explains price hikes are “consistent with Gilead’s historical practice,” since the drug maker has typically raised prices once per year during the first quarter. He adds that Gilead will not recognize the full magnitude of the price increases because of discounts, rebates, and regulations.
The Alliance for Patient Access, a nonprofit group that gives off a consumer-friendly vibe, is running ads warning that a Trump administration proposal to apply international pricing to certain Medicare drugs would be a nightmare for seniors, but is bankrolled by the pharmaceutical industry, the Associated Press reports. The group is also closely aligned with a Washington lobbying and public relations firm, Woodberry Associates, whose president, Brian Kennedy, is the nonprofit’s executive director.
About the Author Reprints
